In April 2025, the European market has shown resilience, with the pan-European STOXX Europe 600 Index rising by nearly 4% over a week, buoyed by the European Central Bank's decision to cut rates amid trade uncertainties. As investors navigate these shifting economic conditions, identifying undervalued stocks becomes crucial; such opportunities often lie in companies whose intrinsic value is not yet reflected in their current market price.
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Cenergy Holdings (ENXTBR:CENER) | €8.42 | €16.43 | 48.8% |
| Mips (OM:MIPS) | SEK352.60 | SEK692.82 | 49.1% |
| LPP (WSE:LPP) | PLN15610.00 | PLN30723.31 | 49.2% |
| Lindab International (OM:LIAB) | SEK186.80 | SEK371.74 | 49.8% |
| Verbio (XTRA:VBK) | €9.24 | €18.22 | 49.3% |
| TF Bank (OM:TFBANK) | SEK345.50 | SEK669.05 | 48.4% |
| Etteplan Oyj (HLSE:ETTE) | €11.55 | €23.07 | 49.9% |
| Stille (OM:STIL) | SEK209.00 | SEK400.76 | 47.8% |
| Komplett (OB:KOMPL) | NOK11.50 | NOK22.67 | 49.3% |
| Fodelia Oyj (HLSE:FODELIA) | €7.14 | €13.91 | 48.7% |
Let's take a closer look at a couple of our picks from the screened companies.
Overview: AddLife AB (publ) and its subsidiaries supply equipment, consumables, and reagents mainly to the healthcare sector, research institutions, colleges, universities, as well as the food and pharmaceutical industries; it has a market cap of approximately SEK18.77 billion.
Operations: The company's revenue is primarily derived from its Labtech segment, which contributes SEK3.80 billion, and its Medtech segment, which generates SEK6.50 billion.
Estimated Discount To Fair Value: 26.9%
AddLife is trading at SEK 154, significantly below its estimated fair value of SEK 210.76, presenting a potential undervaluation based on discounted cash flow analysis. Despite low forecasted return on equity and interest payments not being well covered by earnings, the company has shown strong profit growth with net income improving to SEK 94 million from a loss last year. Future earnings are expected to grow significantly faster than the Swedish market average.
Overview: Mayr-Melnhof Karton AG manufactures and sells cartonboard and folding cartons in Germany, Austria, and internationally, with a market cap of €1.56 billion.
Operations: The company's revenue segments include MM Board & Paper with €1.95 billion, MM Food & Premium Packaging at €1.70 billion, and MM Pharma & Healthcare Packaging contributing €615.69 million.
Estimated Discount To Fair Value: 38.2%
Mayr-Melnhof Karton is trading at €77.8, significantly below its estimated fair value of €125.91, highlighting a potential undervaluation based on discounted cash flow analysis. Despite having a high level of debt and a forecasted low return on equity, the company's earnings are expected to grow significantly faster than the Austrian market over the next three years. Analysts anticipate a stock price rise by 30.9%, supported by recent dividend increases to €1.80 per share.
Overview: Verbio SE is involved in the production and distribution of fuels and finished products across Germany, Europe, North America, and internationally, with a market cap of €588.73 million.
Operations: The company's revenue is primarily derived from its Biodiesel segment, which generated €856.58 million, and its Bioethanol (including Biomethane) segment, which contributed €636.48 million.
Estimated Discount To Fair Value: 49.3%
Verbio SE is trading at €9.24, well below its estimated fair value of €18.22, suggesting a potential undervaluation based on cash flow analysis. Despite recent earnings setbacks with a net loss reported for the latest quarter and six months, production of biodiesel, bioethanol, and biomethane has increased compared to last year. Analysts expect Verbio to become profitable within three years and forecast revenue growth above the German market average.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com